APOE and Alzheimer disease: Interestingly, in humans and transgenic mice, APOE4 carriers have lower levels of APOE protein in the brain compared to noncarriers [80,81], and human patients carrying APOE4 develop AD 8–15 y earlier than carriers of APOE2 or APOE3 [38,62].